I H Nauta1, M M Rietbergen1, A A J D van Bokhoven1, E Bloemena2, B I Lissenberg-Witte3, D A M Heideman4, R J Baatenburg de Jong5, R H Brakenhoff6, C R Leemans1. 1. Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, Cancer Center Amsterdam, The Netherlands. 2. Department of Oral and Maxillofacial Surgery/Oral Pathology, VU University Medical Center Amsterdam, The Netherlands; Academic Center for Dentistry Amsterdam (ACTA), The Netherlands; Departments of Pathology. 3. Epidemiology and Biostatistics, VU University Medical Center, Cancer Center Amsterdam, The Netherlands. 4. Departments of Pathology. 5. Department of Otorhinolaryngology/Head and Neck Surgery, Erasmus Medical Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. 6. Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, Cancer Center Amsterdam, The Netherlands. Electronic address: rh.brakenhoff@vumc.nl.
Abstract
Background: Oropharyngeal squamous cell carcinomas (OPSCCs) are traditionally caused by smoking and excessive alcohol consumption. However, in the last decades high-risk human papillomavirus (HPV) infections play an increasingly important role in tumorigenesis. HPV-driven OPSCCs are known to have a more favorable prognosis, which has led to important and marked changes in the recently released TNM-8. In this 8th edition, OPSCCs are divided based on p16 immunostaining, with p16 overexpression as surrogate marker for the presence of HPV. The aims of this study are to evaluate TNM-8 on a Dutch consecutive cohort of patients with p16-positive OPSCC and to determine the relevance of additional HPV DNA testing. Patients and methods: All OPSCC patients without distant metastases at diagnosis and treated with curative intent at VU University Medical Center (2000-2015) and Erasmus Medical Center (2000-2006) were included (N = 1204). HPV status was determined by p16 immunostaining followed by HPV DNA PCR on the p16-immunopositive cases. We compared TNM-7 and TNM-8 using the Harrell's C index. Results: In total, 388 of 1204 (32.2%) patients were p16-immunopositive. In these patients, TNM-8 had a markedly better predictive prognostic power than TNM-7 (Harrell's C index 0.63 versus 0.53). Of the 388 p16-positive OPSCCs, 48 tumors (12.4%) were HPV DNA-negative. This subgroup had distinct demographic, clinical and morphologic characteristics and showed a significantly worse five-year overall survival compared with the HPV DNA-positive tumors (P < 0.001). Conclusions: TNM-8 has a better predictive prognostic power than TNM-7 in patients with p16-positive OPSCC. However, within p16-positive OPSCCs, there is an HPV DNA-negative subgroup with distinct features and a worse overall survival, indicating the importance to perform additional HPV DNA testing when predicting prognosis and particularly for selecting patients for de-intensified treatment regimens.
Background: Oropharyngeal squamous cell carcinomas (OPSCCs) are traditionally caused by smoking and excessive alcohol consumption. However, in the last decades high-risk human papillomavirus (HPV) infections play an increasingly important role in tumorigenesis. HPV-driven OPSCCs are known to have a more favorable prognosis, which has led to important and marked changes in the recently released TNM-8. In this 8th edition, OPSCCs are divided based on p16 immunostaining, with p16 overexpression as surrogate marker for the presence of HPV. The aims of this study are to evaluate TNM-8 on a Dutch consecutive cohort of patients with p16-positive OPSCC and to determine the relevance of additional HPV DNA testing. Patients and methods: All OPSCC patients without distant metastases at diagnosis and treated with curative intent at VU University Medical Center (2000-2015) and Erasmus Medical Center (2000-2006) were included (N = 1204). HPV status was determined by p16 immunostaining followed by HPV DNA PCR on the p16-immunopositive cases. We compared TNM-7 and TNM-8 using the Harrell's C index. Results: In total, 388 of 1204 (32.2%) patients were p16-immunopositive. In these patients, TNM-8 had a markedly better predictive prognostic power than TNM-7 (Harrell's C index 0.63 versus 0.53). Of the 388 p16-positive OPSCCs, 48 tumors (12.4%) were HPV DNA-negative. This subgroup had distinct demographic, clinical and morphologic characteristics and showed a significantly worse five-year overall survival compared with the HPV DNA-positive tumors (P < 0.001). Conclusions: TNM-8 has a better predictive prognostic power than TNM-7 in patients with p16-positive OPSCC. However, within p16-positive OPSCCs, there is an HPV DNA-negative subgroup with distinct features and a worse overall survival, indicating the importance to perform additional HPV DNA testing when predicting prognosis and particularly for selecting patients for de-intensified treatment regimens.
Authors: Bhishamjit S Chera; Sunil Kumar; Brian T Beaty; David Marron; Stuart Jefferys; Rebecca Green; Emily C Goldman; Robert Amdur; Nathan Sheets; Roi Dagan; D Neil Hayes; Jared Weiss; Juneko E Grilley-Olson; Adam Zanation; Trevor Hackman; Jeffrey M Blumberg; Samip Patel; Mark Weissler; Xianming M Tan; Joel S Parker; William Mendenhall; Gaorav P Gupta Journal: Clin Cancer Res Date: 2019-05-14 Impact factor: 12.531
Authors: Tom Bradish; H Fisher; V Paleri; M Robinson; D Meikle; C Kelly; J O'Hara Journal: Eur Arch Otorhinolaryngol Date: 2020-07-03 Impact factor: 2.503
Authors: Bernhard G Weiss; Mahalia Zoe Anczykowski; Stefan Küffer; Jennifer L Spiegel; Mattis Bertlich; Martin Canis; Friedrich Ihler; Julia Kitz; Mark Jakob Journal: Eur Arch Otorhinolaryngol Date: 2020-08-20 Impact factor: 2.503
Authors: Stephanie G Craig; Lesley A Anderson; Michael Moran; Laura Graham; Keith Currie; Keith Rooney; Max Robinson; Victoria Bingham; Kate S Cuschieri; Stephen McQuaid; Andrew G Schache; Terry M Jones; Dennis McCance; Manuel Salto-Tellez; Simon S McDade; Jacqueline A James Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-10-30 Impact factor: 4.090